Results 51 to 60 of about 4,535 (170)

ACE2‐ and HR2‐Mimetic Peptides Inhibit Replication of Two SARS‐CoV‐2 Variants

Journal of Medical Virology, Volume 98, Issue 7, July 2026.
ABSTRACT Several therapeutic approaches to inhibiting severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) focus on blocking the virus's entry mechanism. This can be blocked in two ways: by interacting with the receptor‐binding domain (RBD) of the spike protein and human angiotensin‐converting enzyme 2 (ACE2), and by blocking viral‐cellular ...
Melvin E. Zúñiga‐Hernández, Karen L. Reyes‐Barrera, Sergio N. Hidalgo‐Figueroa, Edgar D. Páez‐Pérez, Clara I. Espitia Pinzón, Ángel G. Alpuche‐Solís   +5 more
wiley   +1 more source

The pivotal role of β‐lactone stereochemistry in the development of SARS‐CoV‐2 Mpro inhibitors

Protein Science, Volume 35, Issue 7, July 2026.
Abstract From the arrival of the SARS‐CoV‐2 coronavirus in 2019 and its associated COVID‐19 pandemic, worldwide efforts have been focused on developing a drug to treat patients. The SARS‐CoV‐2 main protease (Mpro) is one of the main targets for drug design due to its key role in the virus replication and its distinguished ability to cleave peptides ...
Katarzyna Świderek, Vicent Moliner
wiley   +1 more source

A Multipart Phase 1 Study to Assess Safety and Pharmacokinetics of Ibuzatrelvir in Healthy Participants and Dose Selection for a Dose‐Ranging Study

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT COVID‐19 continues to be a threat to global health and a burden on healthcare systems. There is an ongoing need for COVID‐19 antiviral therapies that are safe and effective across broad patient populations. Ibuzatrelvir is a potent, selective inhibitor of the SARS‐CoV‐2 main protease and demonstrated favorable properties for clinical ...
Ravi Shankar P. Singh, Sima S. Toussi, Frances Hackman, Mona Shahbazi, John Prybylski, Siddhee A. Sahasrabudhe, Penelope Crownover, Eugene P. Kadar, Billy T. George, Negar Niki Alami, Arthur Bergman   +10 more
wiley   +1 more source

Structural analysis of the flexibility of the Ubl2 domain within the papain‐like protease of SARS‐CoV‐2

Acta Crystallographica Section F, Volume 82, Issue 6, Page 222-230, June 2026.
The ubiquitin‐like domain 2 (Ubl2) of the SARS‐CoV‐2 virus is necessary for the stability and catalytic efficiency of its papain‐like protease (PLpro). Our crystallographic study reveals that the Ubl2 domain exhibits notable flexibility and can adopt a conformation that places itself away from the PLpro catalytic domain, representing a new conformation
Gian Luca Freiherr von Scholley, Martina Schaefer, Mark D. Tully, Marc-Andre Hograindleur, Montserrat Soler-López, Roman C. Hillig, Christoph Mueller-Dieckmann, Eaazhisai Kandiah   +7 more
wiley   +1 more source

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore

BMC Public Health
Introduction Antiviral treatment can reduce the burden of COVID-19. But utilisation can be suboptimal, even in a setting like Singapore where it is fully subsidized for those with selected medical conditions and older adults (≥ 50 years).
Sheng En Alexius Matthias Soh, Wei Ling Brenda Ong, Tun-Linn Thein, Konstadina Griva, I.-Cheng Mark Chen   +4 more
doaj   +1 more source

Inhibitors Targeting SARS‐CoV‐2 Papain‐Like Protease: Screening, Design, Synthesis, and Biological Evaluation

ChemMedChem, Volume 21, Issue 9, 14 May 2026.
In our study, we obtained both non‐covalent and covalent PLpro inhibitors. Additionally, the stable protein‐ligand interactions of the active compound were examined using advanced computational docking and molecular dynamics simulations. The non‐covalent inhibitor 2t showed antiviral activity with an EC50 of 2.89 µM, indicating its potential as a ...
Elena‐Oriana Iuga, Nilu Gone, Mariana Ortiz de Godoy, Gabriel Correa Verissimo, Giovanna de Jesus Agostinetto, Liam Urich, Nadine Krüger, Thales Kronenberger, Rafael Victorio Carvalho Guido, Anthony J. O’Donoghue, Stefan A. Laufer, Thanigaimalai Pillaiyar   +11 more
wiley   +1 more source

Comparative evaluation of authorized drugs for treating Covid‐19 patients

Health Science Reports, 2022
Background and Aims Vaccines are the first line of defense against coronavirus disease 2019 (Covid‐19). However, the antiviral drugs provide a new tool to fight the Covid‐19 pandemic.
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, Md. Rabiul Islam   +3 more
doaj   +1 more source

Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID^®) with Concomitant Medications in Real-World Clinical Settings

Pathogens
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid®. This
Petra Zatovkaňuková, Dalibor Veselý, Jiří Slíva   +2 more
doaj   +1 more source

A Phase 1 Multiple‐Dose, Open‐Label, Pharmacokinetic Study of Nirmatrelvir/Ritonavir in Healthy Lactating Women

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT In accordance with the Centers for Disease Control and Prevention recommendations, pregnant women and those with a recent pregnancy (i.e., lactating) are considered at high risk of developing severe COVID‐19 and qualify for treatment with nirmatrelvir/ritonavir.
Jacqueline Gerhart, Narayan Cheruvu, Kathleen Pelletier, Kyle Matschke, Haihong Shi, Josué Kunjom Mfopou, Jennifer Hammond, Ravi Shankar P. Singh   +7 more
wiley   +1 more source

2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition

ChemMedChem, Volume 21, Issue 7, 14 April 2026.
A SAR study led to the identification of new 2‐phenylquinoline‐based derivatives that exhibit anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) activity by acting as ATP‐competitive inhibitors of nonstructural protein 13 (nsp13) helicase.
Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Jacopo Spezzini, Alma Martelli, Simone Brogi, Francesca Esposito, Tommaso Felicetti, Serena Massari, Giuseppe Manfroni, Stefano Sabatini, Gianluca Sbardella, Stefano Alcaro, Johan Neyts, Angela Corona, Enzo Tramontano, Steven De Jonghe, Oriana Tabarrini   +24 more
wiley   +1 more source